KeyCorp Issues Positive Forecast for BioLife Solutions (NASDAQ:BLFS) Stock Price

BioLife Solutions (NASDAQ:BLFS) had its target price raised by KeyCorp from $30.00 to $33.00 in a research report report published on Friday,Benzinga reports. The firm currently has an overweight rating on the medical equipment provider’s stock.

Other analysts have also recently issued research reports about the company. TD Cowen lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. HC Wainwright decreased their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Finally, Craig Hallum upped their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $28.29.

BioLife Solutions Price Performance

BioLife Solutions stock opened at $26.70 on Friday. The firm’s 50-day moving average is $24.62 and its two-hundred day moving average is $23.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The stock has a market capitalization of $1.24 billion, a P/E ratio of -25.19 and a beta of 1.91. BioLife Solutions has a 12-month low of $13.99 and a 12-month high of $28.88.

Insiders Place Their Bets

In other news, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total transaction of $77,118.40. Following the transaction, the executive now directly owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. The trade was a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Aby J. Mathew sold 25,000 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $21.17, for a total transaction of $529,250.00. Following the sale, the executive vice president now directly owns 302,046 shares of the company’s stock, valued at approximately $6,394,313.82. The trade was a 7.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,313 shares of company stock worth $1,572,899 over the last ninety days. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioLife Solutions

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BLFS. Barclays PLC lifted its stake in shares of BioLife Solutions by 20.1% in the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock worth $1,613,000 after acquiring an additional 10,803 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after buying an additional 18,473 shares during the last quarter. State Street Corp boosted its stake in shares of BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after buying an additional 95,788 shares during the last quarter. Stifel Financial Corp grew its position in shares of BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after buying an additional 670 shares in the last quarter. Finally, Mark Sheptoff Financial Planning LLC bought a new stake in shares of BioLife Solutions in the third quarter worth $28,000. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.